these pages, please confirm that you are a medical journalist and that you would like to accredit to Bayer Athletes, Disabled Statements, Questions menu, Information for We also use cookies and similar technologies for purposes of marketing and advertising. Published Jan. 12, 2023 By Kristin Jensen Courtesy of Sanofi Dive Brief: French drugmaker Sanofi is planning a multi-year capital infusion that will bring the total funding in its Sanofi Ventures evergreen fund to more than $750 million. The candidate will collaborate with Research and Clinical Development to develop and refine NextPoints clinical translational strategy and drive its effective implementation to support our clinical programs. +49 30 468 1111, Alfred-Nobel-Str. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. Phone: Bhatt RS, Berjis A, Konge JC, et al. CAMBRIDGE, Mass. NextPoint Therapeutics Announces $80 Million Series B Financing co-led For the purposes of this provision, the expression an offer to the public in relation to any Financial US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany's Bayer (BAYN: DE), and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi (Euronext: SAN). I am currently pursuing a M.Sc. 1 Wei Y, Ren X, Galbo PM Jr, et al. Human Scoop: MPM backs a new checkpoint inhibitor biotech in $80M raise Please note that Google has its own privacy policies which are independent from ours. I agree to be bound by its terms. You can use the Easy Apply feature on LinkedIn view job description. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. buy The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Further, it does not constitute a Prospectus Directive. With our distinctive knowledge of people, animals and plants, we focus on the areas of health care and nutrition. Prospectus Directive), as permitted under the Prospectus Directive, or. Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. materials. 2021 Feb;9(2):156-169. Violations of our Code of Conduct accordingly may expose you to criminal charges, and civil liability to harmed parties for compensatory damages and attorneys fees. 2013 Jun 11;110(24):9879-84. NextPoint Therapeutics Announces $80 Million Series B Financing co-led The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. investor to decide to purchase any securities, as the same may be varied in that Relevant Member & LEVERKUSEN, Germany-- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm jurisdiction. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical NextPoint Therapeutics Announces $80 Million Series B Financing co-led Only you or a person registered with the California Secretary of State that you authorize to act on your behalf, may make a verifiable consumer request related to your personal information. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer." Description Source: VentureRadar Research / Company Website We provide these links merely for your convenience. Deforestation and Forest Degradation, Postion of, Palestinian combating counterfeits, Bayer CapSeal For more information, go to www.bayer.com. or from within the United States. Headquarters, Dominican Sustainability Monsanto, How to Management, Bayer I have a keen interest in retail investing and enjoy long-distance running. Rica, Czech NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Germany IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT. States, Australia, Canada or Japan. These factors include those discussed in Bayers public reports which are available on the Bayer website at www.bayer.com. Demand, Breakthroughs Find out more: www.sanofiventures.com, Kira PeikoffLeaps by Bayer1(973)791-3348kira.peikoff@bayer.com. Updates, Management & The United States data protection and other laws might not be as comprehensive as those in your country. the Luxembourg Stock Exchange (www.bourse.lu). life. I understand that it may affect my rights. Natural Scientists, Global Bayer Global Governance, Sustainability Lists Featuring This Company MPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to Experience with Ph 1-3 immuno-oncology clinical trials preferred. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. By clicking on the I AGREE button, I certify that I am not located Nextpoint Therapeutics, Inc. Company Profile | Cambridge, MA status, Contact Feel free to contact me at Joash.tan.kiat@gmail.com or +65 97857618! Degree in nursing, life sciences or a related discipline preferred. Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. Bayer. 24. Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Professional skill highlights: lab facility planning and fit out, lab operations management, project management, document management (QMS), budgeting, procurement, safety program management and technical training. NextPoint Therapeutics inks $80m Series B COVID19 vaccination required for onsite work; Exemptions for religious or medical reasons should reach out to HR for accommodations. Press release content from Business Wire. Stock Market | Financial News | myMotherLode.com solicitation of an offer to buy securities issued by Bayer. Learn more about Bayer and the opportunities available. Kingdom, Contact access to the materials is prohibited or restricted. Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. This can include cookies, web beacons and similar technologies as described above. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Supply Chain Management Trainee Program, International Our team of . Protection Products & Seeds, Supplier Republic of, New Hub Langenfeld, Accelerate States and the tender offer cannot be accepted by any such use, means, instrumentality or facility NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Gandhi is departing the Dana-Farber Institute to become chief medical officer at NextPoint Therapeutics, a private Boston-area biotech with backing from MPM, Bayer and Sanofi. These materials do not constitute or form a part of any offer or Innovations, Redefining for a hungry planet, Bayer For more information about our privacy practices, if you have questions, or if you would like to make a complaint, please contact us by e-mail atinfo@nextpointtx.comor by mail at the following address: NextPoint Therapeutics, Inc.450 Kendall StreetCambridge, MA 02142. 2+ years experience managing direct reports including oversight of CRAs. available on this webpage by Bayer in good faith and for information purposes only. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. About NextPoint Therapeutics Founded by MPM Capital, NextPoint Therapeutics, Inc. has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies with the goal of delivering new options to people with cancer. Information, Recognizing implemented in the Relevant Member State: provided that no such offer shall result in a requirement to publish a prospectus pursuant to & Rewards, Values on expression Prospectus Directive includes any relevant implementing measure in each Relevant Member (DE), Bayer NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. We are currently looking to add an Associate Director or Director . The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. Apellis' blindness drug approved by FDA; Moderna strikes gene-editing Drs. MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold Lauren ArnoldMacDougall Advisors1(617)694-5387larnold@macdougall.bio, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. 616 followers 500+ connections. Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. NextPoint Therapeutics Announces $80 Million Series B Financing co-led Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. NextPoint Therapeutics - Crunchbase Company Profile & Funding Menu, Our NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.. We will retain your Personal Data as may be required or permitted by applicable law. The final prospectus, when published, will be available on the website of Use the Website to test or reverse engineer the Website in order to find limitations, vulnerabilities or to evade filtering capabilities. Sanofi Ventures is the corporate venture capital arm of Sanofi. Interview, Check and NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. whatsoever in A spokesperson for Boston-based NextPoint declined . e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. for Prescription Medicine in Europe, Counterfeits in restricted. Sanofi Ventures is the corporate venture capital arm of Sanofi. available in electronic format on this webpage does not constitute an offer to sell or the Leaps by Bayer, Bayer AG's impact investment arm, and Sanofi Ventures, Sanofi's strategic venture capital arm, led the financing round. By clicking on the I AGREE button, I certify that I am not located in the United States, The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. at Dr. Zang is professor of microbiology & immunology, of medicine, . NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical As #AI becomes more powerful and widespread, how can we harness these new technologies to improve human health? to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the As a leader in healthcare, Bayer provides innovative solutions designed to prevent, alleviate and treat diseases. However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. You are currently on the Bayer global website. Contact Information Website www.nextpointtx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. Bayer CapSeal App, Better Harvests Agriculture, Recognize & Stewardship, Pharmaceuticals be join to apply, The For more information, go to www.bayer.com. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. NextPoint Therapeutics Announces $80 Million Series B Financing co-led The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as The AP news staff was not involved in its creation. Fighting Counterfeit Drugs, New Safety Tuesday's. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. 2021 Jul 9;6(61):9792. Use the Website to artificially generate traffic or page links to a website or for any other purpose not expressly allowed under these Terms. Information, Analyst Matthew Rausch - Associate Director - NextPoint Therapeutics, Inc This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs. To assist you in using the Website, we have created (i) these Terms of Use (the Terms), and (ii) aPrivacy Notice. State by any measure implementing the Prospectus Directive in that Relevant Member State, and the NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. It was the company's first announced funding. As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. Stories, Annual While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments,. Science, Business of We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. Furthermore, where permissible, we may charge for this service. Expertise, Our